Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1838 1
1900 1
1903 3
1905 1
1907 1
1908 1
1910 3
1911 4
1912 3
1913 2
1915 1
1916 1
1917 3
1918 3
1920 1
1922 2
1923 3
1924 12
1925 2
1926 1
1927 1
1928 3
1930 1
1931 2
1932 4
1933 2
1934 2
1935 3
1936 5
1937 1
1939 1
1941 1
1945 8
1946 36
1947 39
1948 42
1949 33
1950 60
1951 63
1952 65
1953 65
1954 67
1955 72
1956 66
1957 76
1958 73
1959 81
1960 69
1961 73
1962 86
1963 155
1964 177
1965 141
1966 138
1967 166
1968 185
1969 180
1970 197
1971 213
1972 200
1973 195
1974 204
1975 191
1976 187
1977 222
1978 192
1979 202
1980 209
1981 209
1982 238
1983 269
1984 249
1985 260
1986 290
1987 284
1988 304
1989 350
1990 321
1991 310
1992 332
1993 372
1994 372
1995 380
1996 393
1997 352
1998 405
1999 371
2000 438
2001 467
2002 451
2003 445
2004 458
2005 517
2006 555
2007 551
2008 616
2009 643
2010 660
2011 749
2012 794
2013 747
2014 839
2015 815
2016 885
2017 951
2018 998
2019 1074
2020 1198
2021 1370
2022 1448
2023 1313
2024 1302
2025 97

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28,615 results

Results by year

Filters applied: . Clear all
Page 1
Myositis Antibodies and Interstitial Lung Disease.
Basuita M, Fidler LM. Basuita M, et al. J Appl Lab Med. 2022 Jan 5;7(1):240-258. doi: 10.1093/jalm/jfab108. J Appl Lab Med. 2022. PMID: 34996093 Review.
The idiopathic inflammatory myopathies (IIM) represent a CTD subtype of growing interest to ILD experts. The expansion and availability of myositis-specific and myositis-associated antibody testing has allowed for improved disease detection and characterization. ... …
The idiopathic inflammatory myopathies (IIM) represent a CTD subtype of growing interest to ILD experts. The expansion and availability of …
Diagnosis, pathogenesis and treatment of myositis: recent advances.
Carstens PO, Schmidt J. Carstens PO, et al. Clin Exp Immunol. 2014 Mar;175(3):349-58. doi: 10.1111/cei.12194. Clin Exp Immunol. 2014. PMID: 23981102 Free PMC article. Review.
Dermatomyositis (DM), polymyositis (PM), necrotizing myopathy (NM) and inclusion body myositis (IBM) are four distinct subtypes of idiopathic inflammatory myopathies - in short myositis. ...The use of magnetic resonance imaging of skeletal muscles and detection of …
Dermatomyositis (DM), polymyositis (PM), necrotizing myopathy (NM) and inclusion body myositis (IBM) are four distinct subtypes of id …
Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies.
Mariampillai K, Granger B, Amelin D, Guiguet M, Hachulla E, Maurier F, Meyer A, Tohmé A, Charuel JL, Musset L, Allenbach Y, Benveniste O. Mariampillai K, et al. JAMA Neurol. 2018 Dec 1;75(12):1528-1537. doi: 10.1001/jamaneurol.2018.2598. JAMA Neurol. 2018. PMID: 30208379 Free PMC article.
DESIGN, SETTING, AND PARTICIPANTS: An observational, retrospective cohort study was performed using a database of the French myositis network. Patients identified from referral centers for neuromuscular diseases were included from January 1, 2003, to February 1, 2016. Of 4 …
DESIGN, SETTING, AND PARTICIPANTS: An observational, retrospective cohort study was performed using a database of the French myositis …
Clinical pearls and promising therapies in myositis.
Connolly CM, Paik JJ. Connolly CM, et al. Expert Rev Clin Immunol. 2023 Jul-Dec;19(7):797-811. doi: 10.1080/1744666X.2023.2212162. Epub 2023 May 18. Expert Rev Clin Immunol. 2023. PMID: 37158055 Free PMC article. Review.
Currently, the challenges of IIMs are multifold, including difficulties in timely diagnosis owing to clinical heterogeneity, limited insights into disease pathogenesis, as well as a restricted number of available therapies. However, advances utilizing myositis-specific aut …
Currently, the challenges of IIMs are multifold, including difficulties in timely diagnosis owing to clinical heterogeneity, limited insight …
Scleromyositis: A distinct novel entity within the systemic sclerosis and autoimmune myositis spectrum. Implications for care and pathogenesis.
Giannini M, Ellezam B, Leclair V, Lefebvre F, Troyanov Y, Hudson M, Senécal JL, Geny B, Landon-Cardinal O, Meyer A. Giannini M, et al. Front Immunol. 2023 Jan 26;13:974078. doi: 10.3389/fimmu.2022.974078. eCollection 2022. Front Immunol. 2023. PMID: 36776390 Free PMC article. Review.
Systemic sclerosis and autoimmune myositis are both associated with decreased quality of life and increased mortality. Their prognosis and management largely depend on the disease subgroups. Indeed, systemic sclerosis is a heterogeneous disease, the two predominant forms o …
Systemic sclerosis and autoimmune myositis are both associated with decreased quality of life and increased mortality. Their prognosi …
Giant cell myositis and myocarditis revisited.
Oflazer P. Oflazer P. Acta Myol. 2020 Dec 1;39(4):302-306. doi: 10.36185/2532-1900-033. eCollection 2020 Dec. Acta Myol. 2020. PMID: 33458585 Free PMC article. Review.
Giant cell myositis (GCMm) and giant cell myocarditis (GCMc) are two rare autoimmune conditions. Among these, GCMc is a life-threatening disease with a 1-year mortality rate of 70%. ...Most commonly co-manifesting conditions with GCMm and/or GCMc are thymoma, myasthenia gr …
Giant cell myositis (GCMm) and giant cell myocarditis (GCMc) are two rare autoimmune conditions. Among these, GCMc is a life-threaten …
Update on Myositis Therapy: From Today's Standards to Tomorrow's Possibilities.
Glaubitz S, Zeng R, Rakocevic G, Schmidt J. Glaubitz S, et al. Curr Pharm Des. 2022;28(11):863-880. doi: 10.2174/1381612827666211115165353. Curr Pharm Des. 2022. PMID: 34781868 Review.
Inflammatory myopathies, in short, myositis, are heterogeneous disorders that are characterized by inflammation of skeletal muscle and weakness of arms and legs. Research over the past few years has led to a new understanding regarding the pathogenesis of myositis. …
Inflammatory myopathies, in short, myositis, are heterogeneous disorders that are characterized by inflammation of skeletal muscle an …
Immune Checkpoint Inhibitor-induced Myositis.
Jayan A, Mammen AL, Suarez-Almazor ME. Jayan A, et al. Rheum Dis Clin North Am. 2024 May;50(2):281-290. doi: 10.1016/j.rdc.2024.02.003. Epub 2024 Mar 12. Rheum Dis Clin North Am. 2024. PMID: 38670726 Review.
Myositis induced by immune checkpoint inhibitors (ICIs) is an infrequent, potentially fatal, immune-related adverse event. ...Patients can present with clinical manifestation symptoms of myositis alone or in combination with myocarditis and/or myasthenia gravis, whi …
Myositis induced by immune checkpoint inhibitors (ICIs) is an infrequent, potentially fatal, immune-related adverse event. ...Patient …
Inclusion body myositis.
Warman-Chardon J, Breiner A, Bourque PR. Warman-Chardon J, et al. CMAJ. 2024 Apr 14;196(14):E486. doi: 10.1503/cmaj.231815. CMAJ. 2024. PMID: 38621777 Free PMC article. No abstract available.
Myositis non-inflammatory mechanisms: An up-dated review.
Manole E, Bastian AE, Butoianu N, Goebel HH. Manole E, et al. J Immunoassay Immunochem. 2017;38(2):115-126. doi: 10.1080/15321819.2017.1298525. J Immunoassay Immunochem. 2017. PMID: 28375073 Review.
28,615 results
You have reached the last available page of results. Please see the User Guide for more information.